SYNthesis med chem opens new facility in Cambridge, UK
SYNthesis med chem, the global contract research organisation providing synthetic and medicinal chemistry services, announced that the company has opened a new facility at the Babraham Research Campus in Cambridge, UK.
SYNthesis operates a unique business model, combining medicinal chemistry expertise located at the company's labs in Melbourne, Australia and now Cambridge, UK with flexible, high quality, cost effective synthetic chemistry expertise provided by the company's synthetic chemists based in Shanghai, China. The opening of this new facility in Cambridge, UK has enabled SYNthesis to add UK-based medicinal chemistry expertise to the organisation and to provide European customers with local project management for all synthetic and medicinal chemistry projects.
Professor Andrew Wilks, co-founder and Executive Chairman of SYNthesis, commented: “With an increasing customer base across Europe it was essential that we put in place the infrastructure and resources to deliver the required levels of support for all our medicinal and synthetic chemistry projects. The new Cambridge facility does that, but also gives us the capacity to grow as we attract new customers.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
